Gate Bioscience expands Lilly drug discovery deal worth more than $870 million

By Reuters News

Oct 5 (Reuters) - Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly LLY.N to develop treatments targeting disease-causing proteins, in a deal potentially worth more than $870 million.

The companies' original agreement, announced in July 2025, was worth up to $856 million.


Here are key details:

  • The expanded collaboration adds one drug target, with an option to add a second

  • Gate will receive an upfront payment and research funding, as well as an additional payment if the second target is selected

  • The companies did not disclose the upfront payment

  • Privately held Gate Bioscience will use its platform to discover oral small-molecule drugs designed to eliminate proteins that have been difficult to target with existing medicines

  • Gate will lead the discovery work, while Lilly will handle late-stage preclinical and clinical development, manufacturing and commercialization

  • Lilly will have exclusive worldwide rights to products developed for the selected targets

  • Gate is also eligible for milestone payments and royalties on global sales

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.